Clinical Trials Directory

Trials / Terminated

TerminatedNCT03648437

Paracetamol And Ibuprofen/Indomethacin in Closing Patent Ductus Arteriosus

Paracetamol And Ibuprofen/Indomethacin in Closing Patent Ductus Arteriosus of Preterm Infants - Randomised, Placebo-controlled Multicentre Trial

Status
Terminated
Phase
Phase 1
Study type
Interventional
Enrollment
22 (actual)
Sponsor
University of Oulu · Academic / Other
Sex
All
Age
4 Months
Healthy volunteers
Not accepted

Summary

The purpose of this pilot trial is to study efficacy and safety of simultaneous intravenous (iv) ibuprofen/indomethacin and paracetamol medications in the closure of patent ductus arteriosus (PDA) in preterm infants. It is randomized, placebo-controlled, double-blind, phase 1, multicenter, clinical trial.

Detailed description

Premature infants (born before 37 weeks gestational age) with patent ductus arteriosus (PDA) are the focus of the study since no trials on the additive efficacy of these two medications on the contraction of ductus arteriosus are available. Preterm infants who are diagnosed to have a hemodynamically significant PDA and who, according to the decision of the attending clinician, need ibuprofen/indomethacin therapy, are eligible to this trial. If the parents deny the consent, the patient will be treated according to the standard PDA treatment: three days' iv ibuprofen Pedea® 5mg/ml solution infusion (Oulu, Helsinki, Tartu) dosing: 10mg/kg + 5mg/kg + 5mg/kg (q24h); or three days' iv indomethacin (Turku) 0.2mg/kg + 0.1mg/kg + 0.1mg/kg (q24h). In case of any contraindications for ibuprofen/indomethacin, the treatment would be surgical ligation.

Conditions

Interventions

TypeNameDescription
DRUGParacetamol 10Mg/mLExperimental drug
DRUG0.45% Sodium ChloridePlacebo comparator
DRUGIbuprofenStandard therapy
DRUGIndomethacinStandard therapy

Timeline

Start date
2018-09-03
Primary completion
2024-10-04
Completion
2024-10-04
First posted
2018-08-27
Last updated
2024-10-18

Locations

4 sites across 1 country: Finland

Source: ClinicalTrials.gov record NCT03648437. Inclusion in this directory is not an endorsement.